Coherus Completes Surface Oncology Acquisition : vimarsana.c

– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will...

Related Keywords

United States , Canada , China , Marek Ciszewski , Denny Lanfear , Jodi Sievers , Coheru Immuno , Coherus Biosciences , Coherus Biosciences Inc , Exchange Commission , Goodwin Procter , Surface Oncology Inc , Vp Corporate Communications , Latham Watkins , Shanghai Junshi Biosciences Ltd , Arnold Porter Kaye Scholer , Wedbush Securities Inc , Nasdaq , Exchange Commission On , Surface Oncology , Chief Executive Officer , Nasdaq Capital Market , Porter Kaye Scholer , Wedbush Securities , Biologics License Application , Private Securities Litigation Reform Act , Coheru Quarterly Report , Markets ,